KAZUISTIKY Ústup retroperitoneální fibrózy po léčbě rituximabem, cyklofosfamidem a glukokortikoidy s následnou udržovací léčbou rituximabem E14 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2023;69(3):E4-E15 / www.casopisvnitrnilekarstvi.cz 34. Laco J, Podhola M, Kamarádová K, et al. Idiopathic vs. secondary retroperitoneal fibrosis: a clinicopathological study of 12 cases, with emphasis to possible relationship to IgG4-related disease. Virchows Archiv. 2013;463(5):721-730. 35. Hermanová M: Idiopatická retroperitoneální fibróza - editorial. Vnitřní lékařství. 2011;57(5):439-440. 36. Michaligová A, Plank L, Ježíková, A, et al. Ormondova choroba (idiopatická retroperitoneálna fibróza). Vnitřní lékařství. 2011;57(5):511-515. 37. Amis ES. Retroperitoneal fibrosis. AJR Am J Roengenol. 1991;157(2):321-329. 38. Sanders RC, Duffy T, Mcloughlin MG, Walsh PC. Sonography in the diagnosis of retroperitneal fibrosis. J Urol. 1977;118(6):944-946. 39. Vivas I, nicolas AI, Velazquez P, Elduayen B, fernandez-Villa T, Martinez-Cuesta A. Retroperitoneal fibrosis: typical and atypical manifestation. Br j Radiol 2000;73(866):214-222. 40. Van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL. Idiopathic retroperitoneal fibrosis: prostective evaluation of incidence and clinicoradiologic presentationn. Medicine (Baltimore) 2009;88(4):193-201. 41. Caiafa RO, Vinuesa AS,Izquierdo RS, Brufau BP, Colella JRA, Molina CN. Retroperitoneal fibrosisi: role of imaging in Diagnosis and Follorw-up. RadioGraphics. 2013 33:2,535-552. 42. Miniberger M, Kašpar M, Drechslerová , et al. Ormondův syndrom (Syndrom retroperitoneální fibrózy). Diagnostické obtíže u necharakteristické formy onemocnění při vyšetření výpočetní tomografií. Česká radiologie. 1998;52(4):214-220. 43. Řehák Z, Němec P, Fabian , et al. Využití pozitronové emisní tomografie (18F-FDG PET) v diagnostice idiopatické retroperitoneální fibrózy – kazuistika Slovenská rádiológia. 2009;16(1):6873. 44. Roussel E, Callemeyn J, Van Moerkercke W. Standardized approach to idiopathic retroperitoneal fibrosis: a comprehensive review of the literature. Acta Clin Belg. 2020;75(4):239-244. 45. Wang K, Wang Z, Zeng Q, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS One. 2021;16(2):e0245601. doi: 10.1371/ journal.pone.0245601. 46. Novák I, Morávek P, Baše J, et al. Dlouhodobé výsledky léčby nemocných s retroperitoneální fibrózou, Rozhledy v chirurgii. 1994;73(6):287-290. 47. Radoňák J, Vajo J, Toncr I, et al. Neobvyklá lokalizovaná forma retroperitoneálnej fibrózy. Rozhledy v chirurgii. 1999;78(8):378-380. 48. van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis.2007;49:615-625. 49. Mizushima I, Inoue D, Yamamoto M, et al. Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis: a retrospective multicenter study. Arthritis Res Ther. 2014;16:R156. doi:10.1186/ar4671 50. Brandt AS, Kamper L, Kukuk S, et al. Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol Int. 2014;93:320-325. 51. van Bommel EF, Pelkmans LG, van Damme H, et al. Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J InternMed. 2013;24:444-450. 52. Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomized controlled trial. Lancet. 2011;378:338-346. 53. Scavalli AS, Spadaro A, Riccieri V, et al. Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis. Clin Rheumatol. 1995;14(4):481-484. 54. Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis. 2013;72:1584–1586. 55. Scavalli AS, Di Rocco G, Giannotti D, et al.Two-years follow-up of low-dose methotrexate and 6-methylprednisolone therapy in a patient with idiopathic retroperitoneal fibrosis. Eur Rev Med Pharmacol Sci. 2012;16(15):2171-4. 56. Binder M, Uhl M, Wiech T, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis. 2012;71:311-312. 57. Kohler HP, Laeng RH, Egger C, et al.Systemische Fibrose (generalisierte Form des Morbus Ormond). Bericht über einen Fall, der mit Cyclophosphamid und Kortikosteroiden eine komplette Remission erlangte Schweiz Med Wochenschr.1995;125(44):2131-6. 58. Colomer Rubio E, Blanes Gallego A, et al. Mesenteric panniculitis with retroperitoneal involvement resolved after treatment with intravenous cyclophosphamide pulses. An Med Interna. 2003;20 (1):31-33. 59. Moroni G, Gallelli B, Banfi G, Sandri S, Messa P, Ponticelli C. Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. Nephrol. Dial. Transplant. 2006;21:2485– 90. 60. Průcha M, Kolombo I, Štádler P. Combination of steroids and azathioprine in the treatment of Ormond’s disease – a single centre retrospective analysis. PragueMed Rep. 2016;117:34–41. doi:10.14712/23362936.2016.3 61. Grotz W, von Zedtwitz I, Andre M, et al.Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids. Lancet. 1998;352(9135):1195. 62. Witschi M, Gugger M, Nicod LP. Treatment of mediastinal fibrosis with mycophenolate mofetil. Respiration. 2009;78(3):330-333. 63. Adler S, Lodermeyer S, Gaa J, et al.Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. Rheumatology (Oxford). 2008;47(10):1535-1538. 64. Jois RN, Kerrigan N, Scott DG. Mycophenolate mofetil for maintenance of remission in idiopathic retroperitoneal fibrosis. Rheumatology (Oxford). 2007;46(4):717-718. 65. Khalil F, Mir MA, Venuto RC. Mycophenolate mofetil in the treatment of retroperitoneal fibrosis. Clin Rheumatol. 2008;27(5):679-681. 66. Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med. 2011;154:31-36. 67. Scheel PJ Jr, Piccini J, Rahman MH, et al.Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. J Urol. 2007;178(1):140-143. 68. Swartz RD, Lake AM, Roberts WW, et al. Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil. Clin Nephrol. 2008;69(4):260-268. 69. Marzano A, Trapani A, Leone N, et al. Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum Dis. 2001;60(4):427-8. 70. Al-Harthy F, Esdaile J, Berean KW, et al. Multifocal idiopathic fibrosclerosis: treatment of 2 cases with cyclosporine. J Rheumatol. 2006;33(2):358-61. PMID: 16465670. 71. Marcolongo R, Tavolini IM, Laveder F, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med. 2004;116:194-197. 72. Maritati F, Corradi D, Versari A, et al. Rituximab therapy for chronic periaortitis. Ann Rheum Dis. 2012;71:1262-1264. 73. Almeqdadi M, Al-Dulaimi M, Perepletchikov A, et al.Rituximab for retroperitoneal fibrosis due to IgG4-related disease: A case report and literature review. Clin Nephrol Case Stud. 2018;6:4-10. 74. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74:1171-1177. 75. Dedinská I, Svetlík D, Adamicova K, et al. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab. Iran J Kidney Dis. 2016;10(5):332-335. 76. Hamdan A, Moeen Z, Tariq H, et al. An Interesting Case of Immunoglobulin G4-Related Retroperitoneal Fibrosis Treated With Rituximab. Cureus. 2021;13(9):e17940. doi:10.7759/cureus.17940. 77. Wallwork R, Wallace Z, Perugino C, et al.Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine (Baltimore). 2018;97(42):e12631. doi: 10.1097/MD.0000000000012631. 78. Boyeva V, Alabsi H, Seidman MA, et al. Use of rituximab in idiopathic; retroperitoneal fibrosis. BMC Rheumatol. 2020;4:40. doi: 10.1186/s41927-020-00140-9. 79. Urban ML, Maritati F, Palmisano A, et al. F. Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. Ann Rheum Dis. 2020;79(3):433-434. 80. Fenaroli P, Maritati F, Vaglio A. Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. Curr Rheumatol Rep. 2021;23(3):18.doi: 10.1007/s11926-020-00966-9. 81. Dattani R, Barwick TD, El Wardany G, et al. RaDaR Rare Disease Group (RDG). An international patient-centred study of retroperitoneal fibrosis. QJM. 2022;115(3):148-154. doi: 10.1093/ qjmed/hcaa327. 82. Hanazono A, Sanpei Y, Shimada H, et al. Remission of idiopathic retroperitoneal fibrosis by ofatumumab as a disease-modifying therapy for multiple sclerosis. eNeurologicalSci. 2022;29:100428. doi: 10.1016/j.ensci.2022.100428. 83. Benucci M, Damiani A, Li Gobbi F, et al. Jaccoud's arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment. Reumatismo.2017;69(2):88-91. 84. Perrotta FM, Fici M, Guerra G, et al. Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report. Clin Exp Rheumatol. 2017;35 Suppl 103(1):226-227. 85. Vaglio A, Catanoso MG, Spaggiari L,et al.. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum. 2013;65(9):2469-75. 86. Loricera J, Blanco R, Castaeda S, et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S79-89. 87. Catanoso MG, Spaggiari L, Magnani L, et al. Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol. 2012;30(5):776-8. 88. Gao H, Liu S, Mai Y, et al. Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis. Ann Rheum Dis. 2023:ard-2022-223736. doi:10.1136/ard2022-223736. 89. Hirose M, Ishimaru Y, Sakata S, et al. Rapid Shrinkage of Retroperitoneal Lymphangioleiomyoma after Sirolimus Initiation. Intern Med. 2022;61(13):2081-2082. doi: 10.2169/internalmedicine.8685-21. 90. Yao W, Li K, Wang Z, et al. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus. Pediatr Dermatol. 2020;37(4):677-680. doi: 10.1111/pde.14157. 91. Lecuelle D, Basille D, Renard C, et al. Highly effective sirolimus therapy for abdominal lymphangioleiomyoma. Respir Med Res. 2019;75:32-34. doi: 10.1016/j.resmer.2019.02.002. 92. Campochiaro C, Della-Torre E, Lanzillotta M, et al. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. Eur J Intern Med. 2020;74:92-98. doi: 10.1016/j.ejim.2019.12.029.
RkJQdWJsaXNoZXIy NDA4Mjc=